TSTetsuya So

Tetsuya So

*This is an algorithmically generated author record based on publicly available information.

Tetsuya So has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Induction of cellular immune response against autologous tumor cells by vaccination with autologous tumor lysate-pulsed dendritic cells

    by Kosei Yasumoto, Tetsuya So, Naohiro Nose, Takashi Yoshimatsu, Mai Tomiyama, Ryuji Maekawa

    • 1 February 2011
      • Vol. 64  (2) , 93

    [Clinical analysis of esophageal cancer associated with other primary cancers].

    by Kenji Ono, Masaru Takenaka, Erina Yokoyama, Soichi Oka, Tetsuro Baba, Tetsuya So, Tomoko So, Hidetaka Uramoto, Mitsuhiro Takenoyama, Takeshi Hanagiri, et al.

    This study aims to investigate the therapeutic and prognostic implications of esophageal cancer in patients with other primary cancer. Between April 1992 and December 2008, in 83 patients underwent surgery for esophageal cancer at our department. Among them, 24 patients (28.9%) had medical history of additional primary cancer. There were 16 metachronous cancers and 8 synchronous cancers. Six patients had antecedent other primary cancers, and subsequent primary cancers developed in 10 patients. The other primary cancers included head and neck cancer in 8 patients, gastric cancer in 8, lung cancer in 6, colorectal cancer in 3, and other cancer in 3. The patients with other primary cancers were both heavy smokers and heavy drinkers in comparison to those without other primary cancers. The post-operative 5-year survival rate in patients with subsequent cancers, antecedent cancers, and synchronous cancers were 100%, 70.0%, and 46.9%. The 5-year survival rate was 33.4% in patients without other primary cancers. A high incidence of multiple primary cancers was observed in patients with esophageal carcinoma but the prognosis of these patients with metachronous cancers are better than that of patient with synchronous cancers and patients without other primary cancers. Post-operative follow up is considered to be necessary for early detection of multiple occurrences of carcinoma, especially in the upper aerodigestive tract.


    • 1 December 2010
      • Vol. 63  (13) , 1101

    [Treatment recommendations for adrenal metastasis of non-small cell lung cancer].

    by Takashi Iwanami, Hidetaka Uramoto, Tetsuro Baba, Masaru Takenaka, Erina Yokoyama, Soichi Oka, Tetsuya So, Kenji Ono, Tomoko So, Mitsuhiro Takenoyama, et al.

    To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC. The patients included 12 males and 5 females with a mean age of 63.9 years. Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively. The mean interval after lung resection and treatment of metachronous adrenal metastasis was 9.9 months. The mean time to progression from treatment of metachronous adrenal metastasis to disease progression was 8.9 months. A survival analysis showed no significant prognostic difference between the patient age, gender, pathological stage, synchronous/metachronous classification, CEA, and site of metastases. However, patients who received an adrenalectomy had a more favorable prognosis. The 2-year survival of patients following resection versus those who did not undergo a resection for adrenal metastasis was 62.5 and 22.8%, respectively. These data indicate that metastatic adrenal tumors should be resected if the patient can tolerate surgery after appropriate selection.


    • 20 August 2010
      • Vol. 95  (2) , 126-9

    Clinicopathologic characteristics of mucinous carcinoma of the breast.

    by Takeshi Hanagiri, Kenji Ono, Teturo Baba, Tetsuya So, Masaharu Yamasaki, Yoshika Nagata, Hidetaka Uramoto, Mitsuhiro Takenoyama, Kosei Yasumoto

    The mucinous carcinoma of breast cancer is a relatively rare malignant tumor. This study investigated the clinical and pathologic features of mucinous carcinoma. The medical records of 237 patients with invasive breast cancer who underwent surgery between 1995 and 2006 were reviewed. These cases included 10 patients (4.2%) with mucinous carcinoma. The age of the patients ranged from 43 to 71 years (mean, 55.5 years). The tumor size was T1 in 5 patients and T2 in 5 patients. Lymph node metastasis was diagnosed as being negative in 9 patients and positive in 1 patient. Six patients (60%) were positive both for estrogen and progesterone receptor. The 10-year survival rates of mucinous carcinoma and other types of invasive breast cancer were 87.5% and 80.7%, respectively. Mucinous carcinoma showed a lower incidence of lymph node metastasis than other types of invasive breast cancer. Mucinous carcinoma tended to have a better prognosis in comparison with other types of invasive breast carcinoma.


    • 12 June 2008
      • Vol. 93  (1) , 50-4

    Results of surgical treatment for lung cancer in young adults.

    by Takeshi Hanagiri, Kenji Sugio, Hidetaka Uramoto, Masakazu Sugaya, Kenji Ono, Tetsuya So, Yoshinobu Ichiki, Shoji Nakata, Tadahiro Nozoe, Toshihiro Osaki, et al.

    In this study, we evaluated the results of surgical treatment in young adults and compared the clinico-pathological features between young and elderly patients. We reviewed the clinical records of 1185 lung cancer patients who underwent surgery in our department. A total of 20 (1.7%) primary lung cancer patients (14 men and 6 women) < or =40 years of age were retrieved. The age range was from 26 to 40 years. Histological type included 10 adenocarcinomas (50%), 3 large cell carcinomas (15%), 3 carcinoids (15%), 2 squamous cell carcinomas (10%), and 2 others. The surgical procedure included 7 (35%) pneumonectomies, 11 (55.0%) lobectomies, and 1 (5%) partial resection. The proportion of pneumonectomies was significantly higher than among elderly patients. Clinical stage was underestimated in 7 of 20 patients, and among these, mediastinal lymph node metastases were revealed by pathological examination in 6 patients. Postoperative 5-year survival rates were 50.2%, 50.4%, and 43.8% in patients < or =40, 41-70, and > or =71 years old, respectively. There were no significant differences in survival rates between younger group and elderly groups. This study suggests that surgical resection is also recommended as the first-line treatment for younger patients with lung cancer.


    • 11 November 2006
      • Vol. 26, 3607-11

    Antigens recognized by IgG derived from tumor-infiltrating B lymphocytes in human lung cancer.

    by Manabu Yasuda, Makiko Mizukami, Takeshi Hanagiri, Yoshiki Shigematsu, Takashi Fukuyama, Yoshika Nagata, Tetsuya So, Yoshinobu Ichiki, Masakazu Sugaya, Mitsuhiro Takenoyama, et al.

    Lung cancer tissues are often infiltrated by B lymphocytes, but it is not clear whether these infiltrations represent tumor-specific immune response or a nonspecific reaction. The serological analysis of recombinant cDNA expression libraries (SEREX) were previously modified using a severe combined immunodeficient (SCID) mice model engrafted with fresh human lung cancer. Here, a panel of antigens recognized by tumor-infiltrating B lymphocytes (TIB) in human lung cancer were characterized. The modified SEREX analysis identified 22 distinct antigens in a large cell carcinoma of the lung. Sequence analysis and real time-PCR analysis showed that 55% of isolated antigens were overexpressed in tumor tissues and 9% had mutation. The results of this study indicate that the humoral immune response of TIB in lung cancer patients can be detected in the xenotransplanted SCID mouse model and our modification shows high sensitivity and specificity for identification of tumor antigens.


    • 11 July 2006
      • Vol. 26, 1827-31

    Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth.

    by Makiko Mizukami, Takeshi Hanagiri, Yoshiki Shigematsu, Tetsuro Baba, Takashi Fukuyama, Yoshika Nagata, Tetsuya So, Yoshinobu Ichiki, Masakazu Sugaya, Manabu Yasuda, et al.

    Tumor-infiltrating B lymphocytes (TIB) are often observed in lung cancer. The role of TIB in tumor growth has not been well investigated. Forty-four surgically-resected human lung cancer tissues were xenotransplanted into SCID mice. Their blood was collected and the volume of the transplanted tumors was measured regularly. The correlations between the IgG titer in the sera and the growth of the transplanted tumors according to the clinicopathological variables were examined. Human IgG production from TIB was observed in the all xenotransplanted mice. Twenty-seven out of the 44 tumors regressed gradually. The average serum human IgG level of the tumor regressors (n = 10) was significantly higher than that of the progressors (n = 9) in squamous cell carcinoma (p = 0.02), while there was no significant difference in the other histological groups. IgG produced by TIB might play a crucial role in preventing tumor growth in squamous cell carcinoma.


  • Descending Necrotizing Mediastinitis. Report of Two Cases.

    by Masayasu Aikawa, Toshihiro Osaki, Tetsuya So, Takashi Yoshimatsu, Koichi Yano, Kosei Yasumoto